<div id="readability-page-1"><ul><li>4 Healthcare Stocks With Massive Gains—and More to Come</li></ul><p>Guardant Health <span>NASDAQ: GH<span></span></span> executives used a Barclays discussion to outline growth drivers across treatment selection, minimal residual disease (MRD) testing, and colorectal cancer (CRC) screening, while addressing investor questions on clinical utility, reimbursement, and commercial execution.</p><div><p><span></span><span>Get <strong>Guardant Health</strong> alerts:</span></p></div><h2>Treatment selection: ESR1 monitoring and Guardant360 expansion</h2> <p>Co-CEO Amirali Talasaz said Guardant Health’s three major business “drivers and brands” are treatment selection, MRD, and screening, and he characterized each as offering “opportunities for hypergrowth.” In treatment selection, he pointed to Guardant360’s role in liquid comprehensive genomic profiling (CGP) and highlighted monitoring for ESR1 mutations in breast cancer as an emerging opportunity. </p><ul><li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li></ul><p>Talasaz said Guardant received FDA approval for ESR1 testing in breast cancer “a couple years ago” for treatment selection, and that shortly after, Guardant’s breast cancer testing volume doubled “in a matter of very few weeks.” He described ESR1 as an emerging resistance mechanism and said it can enable other treatment opportunities for patients. </p><p>Discussion centered on the SERENA-6 trial, in which Guardant’s pharmaceutical partner AstraZeneca is monitoring patients to detect ESR1 in blood and using it as a surrogate marker to guide a treatment switch. Talasaz said the trial readout was discussed at ASCO and that an FDA decision is expected in the first half of the year. He noted the company’s view that ESR1 is “uniquely” detectable via liquid biopsy and framed the opportunity as a shift from single time-point testing at progression to multiple time points of testing during a treatment course. </p><ul><li>3 Fast-Growing Stocks Analysts See Doubling in Price</li></ul><p>Looking to the commercial implications, Talasaz estimated about 40,000 breast cancer patients could be candidates for this type of monitoring if the associated drug is approved for the indication, with testing potentially occurring three to four times per year. He said Guardant has not included this opportunity in its 2026 guidance and prefers to wait for FDA approval before incorporating it into expectations, then assess the post-approval volume impact. </p><p>Talasaz added that the program would be associated with AstraZeneca’s drug and would represent a new companion diagnostic (CDx) for Guardant360—what he called the first “monitoring CDx” for the test. He said Guardant360 already has 25 approvals, but described those as linked to single time-point treatment decision-making rather than monitoring.  </p><h2>CRC FDA approval, reimbursement conversations, and payer dynamics</h2> <p>Talasaz also discussed an FDA approval Guardant360 received in January for CRC, describing it as the company’s first approval for Guardant360 in that indication. While he said CGP utility in CRC is well established, he argued that FDA-approved indications can increase physician confidence and utilization. He also said such approvals can strengthen discussions with commercial payers and potentially help address remaining reimbursement gaps. </p><p>After “10 years,” Talasaz said Guardant360 reimbursement is in a strong position overall, though he acknowledged there are still cases where the company does not receive good payment from payers. He said the company’s experience is that FDA approvals can improve payer conversations for specific indications, potentially supporting coverage and average selling price (ASP) over time, though he emphasized it would take time to realize.  </p><h2>Platform strategy: genomic and epigenomic data, “Smart Apps,” and MetaSight</h2> <p>In response to questions about technology direction, Talasaz emphasized Guardant’s “data moat” and “flywheel of data,” citing genomic data from 1 million patients and “many hundreds of thousands” of patients with full epigenomic data. He described epigenomics as the “dark matter of biology” in cancer understanding and said the dataset is already paying dividends in technology and application development. </p><p>As an example, he said Guardant has developed “Smart Apps” that generate clinical information for physicians, including an application for patient subtyping enabled by the company’s database. Talasaz said the company is layering additional data sources “step by step” and referenced the recent acquisition of MetaSight as adding a complementary technology layer that could extend insights beyond ctDNA, genomics, and epigenomics and potentially improve products across the portfolio.  </p><h2>Reveal MRD: growth, surveillance pull-through, and Reveal Ultra timing</h2> <p>CFO Mike Bell said Guardant does not break out Reveal volumes, but he indicated the analyst’s estimate of roughly 60,000 tests was “broadly in the right ballpark.” Bell said Reveal has been Guardant’s fastest-growing oncology product by volume for the last few years and that the company expects it to remain so this year. He also said the company is “very bullish” on Reveal for 2026. </p><p>On surveillance testing frequency, Bell said CRC surveillance reimbursement has been in place for roughly 12 months and that the company is seeing good traction and pull-through. He said commercial operations have been focusing on the surveillance aspect and improving mechanisms to pull patients through to subsequent tests, adding that tests per patient are improving. </p><p>Talasaz discussed a longer-term vision for MRD that could extend beyond a binary positive/negative result. He described a future where MRD testing could help determine not only whether residual disease is present, but also where it is located and how it can be characterized—though he said this is not “prime time” and framed it as an aspirational direction. </p><p>Regarding Reveal Ultra, Talasaz said Guardant is currently a leader in tumor-naïve MRD and is moving into tumor-informed MRD with Ultra, built on a new technology stack. He said the product is on track to launch later this year, but that it is not included as a revenue contributor in 2026 because it will be new, likely without immediate reimbursement at launch, and subject to adoption dynamics. Bell said reimbursement for Ultra is “to be determined,” noting that CRC reimbursement is $1,644 and that a base case assumption would place Ultra in that ballpark, pending the MolDX process. </p><p>Asked about the technology enabling low detection limits, Talasaz said the company has not disclosed details of the technology stack, but suggested more information will be shared closer to launch.  </p><h2>Shield CRC screening: care-gap focus, sales execution, and Quest partnership</h2> <p>On screening, Talasaz described Shield as “probably the biggest diagnostic brand ever” and said that in its first full year of launch, it was the best diagnostic launch outside of COVID testing. He said Guardant’s messaging is focused on unscreened patients in primary care settings, describing a “54 million patient opportunity.” Talasaz said that based on the medical information Guardant has, about 90% of Shield-tested patients had not been screened in the prior five years, which he said indicates the company is filling a care gap. </p><p>Bell said Guardant’s guidance includes an expectation of 150% volume growth and that the assumptions are primarily driven by commercial execution rather than inclusion in guidelines or quality metrics. He said the company has not baked in inclusion in American Cancer Society (ACS) guidelines, USPSTF, or quality metrics such as HEDIS, describing ACS inclusion as a potential near-term upside. Bell emphasized increasing productivity from the existing 300 sales reps, adding reps and territories, and the launch of a direct-to-consumer (DTC) campaign, which he said is showing promising early signs. </p><p>Bell also pointed to a newly announced partnership with Quest, which he said will help fast-track electronic medical record (EMR) connectivity and is included in guidance. However, he said Guardant has not included potential incremental upside from Quest reps educating their accounts about Shield, calling it a possible additional driver if it proves effective. </p><p>Talasaz said the launch has been targeted toward clinicians experienced with non-invasive CRC screening and toward high-volume Medicare beneficiary practices, reflecting reimbursement status at launch. While he said the company now has nationwide coverage, he noted there are about 250,000 potential primary care physicians with CRC screening experience and said Guardant is “just scratching the surface.” He added that the company remains focused on unscreened patients rather than directly competing for share with stool-based testing, while acknowledging it is seeing some unpromoted use cases such as re-screening patients switching modalities and testing between colonoscopy intervals. </p><p>On DTC, Talasaz said the company is targeting patients 45 and older and “double indexing” on those 65 and older. He characterized the campaign as not yet “full force,” but said Guardant is pleased with early results.</p><h2>About Guardant Health <span>NASDAQ: GH<span></span></span></h2><p>Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.  </p><p>The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Guardant Health</li><li>The gold chart Wall Street is terrified of…</li><li>Elon Musk already made me a “wealthy man”</li><li>Silver paying 20% dividend. Plus 68% share gains</li><li>Unlocked: Elon Musk’s Next Big IPO</li><li>1,500 Banks Just Handed the Fed Your Bank Account</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2><p>Before you consider Guardant Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

<p>Guardant Health executives highlighted growth opportunities in treatment selection, minimal residual disease (MRD) testing, and colorectal cancer (CRC) screening during a Barclays conference. Co-CEO Amirali Talasaz discussed the potential for hypergrowth in these areas, particularly with the FDA-approved ESR1 testing for breast cancer and the recent CRC approval for Guardant360. The company aims to enhance physician confidence and payer discussions through these approvals, while also leveraging genomic and epigenomic data to develop new technologies and applications. CFO Mike Bell noted that Reveal has been the fastest-growing oncology product for Guardant.</p>

Market Beat

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

iShares Genomics Immunology and Healthcare ETF

Guardant Health

Guardant Health Touts Hypergrowth in Guardant360, Reveal MRD and Shield CRC at Barclays Conference